Press release article from our research archive:

ViaCell Acquires Cerebrotec to Form Neuroscience Division.

Noted Neuroscientist, Dr. Seth Finklestein, to Head New

Division Focusing on Cellular and Molecular Medicines for

The Treatment of Stroke and Other Neurological Diseases

BOSTON, July 25 /PRNewswire/ --

ViaCell, Inc., a premier cellular pharmaceuticals company, today announced it has acquired Boston-based Cerebrotec, a neuroscience company focused on the development of novel therapeutic products for stroke recovery.

The ViaCell Neuroscience Division will be formed as a result of this acquisition and will combine Cerebrotec's research in the use of stem cells and neurotrophic growth factors for treatment of stroke with ViaCell's patented Selective ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!